Drugs / CLL442
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03333694 | Dec 2017 → Nov 2018 | skin squamous cell carcinoma in situ | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLL442 | “Cutaneous Cream application twice daily with experimental (CLL442)” NCT03333694 ↗ |
| Route | Topical | “Cutaneous Cream application twice daily with experimental (CLL442)” NCT03333694 ↗ |